PMID- 7688769 OWN - NLM STAT- MEDLINE DCOM- 19930915 LR - 20181130 IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 92 IP - 2 DP - 1993 Aug TI - Keratinocyte growth factor and hepatocyte growth factor/scatter factor are heparin-binding growth factors for alveolar type II cells in fibroblast-conditioned medium. PG - 969-77 AB - Epithelial-mesenchymal interactions mediate aspects of normal lung growth and development and are important in the restoration of normal alveolar architecture after lung injury. To determine if fibroblasts are a source of soluble growth factors for alveolar type II cells, we investigated the effect of fibroblast-conditioned medium (CM) on alveolar type II cell DNA synthesis. Serum-free CM from confluent adult human lung fibroblasts was concentrated fivefold by lyophilization. Type II cells were isolated from adult rats by elastase dissociation and incubated with [3H]thymidine and varying dilutions of concentrated CM and serum from day 1 to 3 of culture. Stimulation of type II cell DNA synthesis by fibroblast-CM was maximal after 48 h of conditioning and required the presence of serum. The activity of the CM was eliminated by boiling and by treatment with trypsin, pepsin, or dithiothreitol and was additive with saturating concentrations of acidic fibroblast growth factor, epidermal growth factor, and insulin. The growth factor activity bound to heparin-Sepharose and was eluted with 0.6 and 1.0 M NaCl. Neutralizing antibody studies demonstrated that the primary mitogens isolated in the 0.6 and 1.0 M NaCl fractions were keratinocyte growth factor (KGF, fibroblast growth factor 7) and hepatocyte growth factor/scatter factor (HGF/SF), respectively. HGF/SF was demonstrated in the crude CM and KGF was detected in the 0.6 M NaCl eluent by immunoblotting. Northern blot analysis confirmed that the lung fibroblasts expressed both KGF and HGF/SF transcripts. Human recombinant KGF and HGF/SF induced a concentration- and serum-dependent increase in rat alveolar type II cell DNA synthesis. We conclude that adult human lung fibroblasts produce at least two soluble heparin-binding growth factors, KGF and HGF/SF, which promote DNA synthesis and proliferation of rat alveolar type II cells in primary culture. KGF and HGF/SF may be important stimuli for alveolar type II cell proliferation during lung growth and after lung injury. FAU - Panos, R J AU - Panos RJ AD - Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611. FAU - Rubin, J S AU - Rubin JS FAU - Csaky, K G AU - Csaky KG FAU - Aaronson, S A AU - Aaronson SA FAU - Mason, R J AU - Mason RJ LA - eng GR - HL-27353/HL/NHLBI NIH HHS/United States GR - HL-29891/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (Culture Media, Conditioned) RN - 0 (Culture Media, Serum-Free) RN - 0 (FGF7 protein, human) RN - 0 (Fgf7 protein, rat) RN - 0 (Fibroblast Growth Factor 10) RN - 0 (Growth Substances) RN - 0 (Insulin) RN - 104781-85-3 (Fibroblast Growth Factor 1) RN - 126469-10-1 (Fibroblast Growth Factor 7) RN - 62031-54-3 (Fibroblast Growth Factors) RN - 62229-50-9 (Epidermal Growth Factor) RN - 67256-21-7 (Hepatocyte Growth Factor) RN - 9007-49-2 (DNA) SB - IM EIN - J Clin Invest 1994 Mar;93(3):1347 MH - Animals MH - Cell Communication MH - Cell Division MH - Cells, Cultured MH - Culture Media, Conditioned MH - Culture Media, Serum-Free MH - DNA/biosynthesis MH - Epidermal Growth Factor/pharmacology MH - Fibroblast Growth Factor 1/pharmacology MH - Fibroblast Growth Factor 10 MH - Fibroblast Growth Factor 7 MH - *Fibroblast Growth Factors MH - Fibroblasts/cytology/*physiology MH - Growth Substances/biosynthesis/*metabolism/*pharmacology MH - Hepatocyte Growth Factor/biosynthesis/*metabolism/pharmacology MH - Humans MH - Insulin/pharmacology MH - Kinetics MH - Lung/cytology/*physiology MH - Pulmonary Alveoli/cytology/drug effects/*metabolism MH - Rats MH - Rats, Sprague-Dawley PMC - PMC294937 EDAT- 1993/08/01 00:00 MHDA- 1993/08/01 00:01 PMCR- 1993/08/01 CRDT- 1993/08/01 00:00 PHST- 1993/08/01 00:00 [pubmed] PHST- 1993/08/01 00:01 [medline] PHST- 1993/08/01 00:00 [entrez] PHST- 1993/08/01 00:00 [pmc-release] AID - 10.1172/JCI116673 [doi] PST - ppublish SO - J Clin Invest. 1993 Aug;92(2):969-77. doi: 10.1172/JCI116673.